MarketCapExport financials
Bio-Techne Corporation (TECH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Bio-Techne Corporation Cash Flow 2026-2008 | TECH
Brief overview of Bio-Techne Corporation's cash flow quality
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow lost 18.3%, moving from $352.2 million to $287.6 million. This is a negative signal for internal funding.
Operating cash flow was positive in all five observations, adding repeatability to the cash profile.
Across five periods, operating cash flow equaled about 1.62x of cumulative net income. Earnings were strongly backed by cash.
Operating cash margin decreased to 23.6% from 37.8% initially. The quality of receipts deteriorated.
Estimated working capital increased by $138.3 million, equal to 11.3% of latest revenue. More cash became tied up in receivables and inventory.
Overall picture
Bio-Techne Corporation retains acceptable cash resilience. Future assessment depends on cash margin, capex and debt trends.
Annual Cash Flow Bio-Techne Corporation
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
292 M | 288 M | 299 M | 254 M | 325 M | 352 M | 205 M | 182 M | 170 M | 144 M | 144 M | - | - | 124 M | 127 M | 127 M | 111 M | 111 M | - |
Depreciation & Amortization |
97.4 M | 110 M | 112 M | 107 M | 101 M | 87.7 M | 82.7 M | 78.2 M | 64.5 M | 60 M | 42.8 M | 37.2 M | 19.2 M | 12.3 M | 12.5 M | 8.7 M | 8.13 M | 7.77 M | - |
Accounts Payables |
26.7 M | 25.3 M | 38 M | 25.7 M | 33.9 M | 29.4 M | 23.1 M | 16.2 M | 18.5 M | 16.9 M | 20.7 M | 13.4 M | 9.65 M | 6.24 M | 6.29 M | 5.21 M | 5.23 M | - | - |
Accounts Receivables |
217 M | 207 M | 241 M | 218 M | 195 M | 145 M | 123 M | 137 M | 120 M | 117 M | 93.4 M | 70 M | 47.9 M | 38.2 M | 35.7 M | 35.9 M | 30.8 M | - | - |
Total Inventories |
196 M | 189 M | 180 M | 172 M | 141 M | 117 M | 103 M | 91 M | 85.6 M | 60.2 M | 57.1 M | 49.6 M | 38.8 M | 34.9 M | 38.3 M | 44.9 M | 13.7 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Bio-Techne Corporation
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 197 M | 110 M | 27.6 M | - | 27.6 M | 84.3 M | 63.9 M | - | 63.9 M | 83.1 M | 59.4 M | - | 59.4 M | 64.4 M | 56.1 M | - | 56.1 M | 120 M | - | - | 48.4 M | 149 M | 66 M | - | 66 M | 155 M | 66 M | - | 40.5 M | 111 M | 39.4 M | - | 39.4 M | 86 M | 39.4 M | - | 44.7 M | 83.9 M | 44.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.6 M | 63.9 M | - | - | 29.3 M | 60.6 M | 29.3 M | - | 34.4 M | 54.9 M | 34.4 M |
Depreciation & Amortization |
- | 73.2 M | 49 M | 24.3 M | 15.5 M | 24.3 M | 18.9 M | 20 M | 18.9 M | 28.1 M | 20.2 M | 20.2 M | - | 28.5 M | 19.4 M | 19.5 M | - | 26.6 M | 53.3 M | 55.7 M | 37.3 M | 24.7 M | 49.8 M | 15.6 M | - | 21.1 M | 42 M | 21.1 M | - | 20.1 M | 40.6 M | 14.3 M | - | 19.1 M | 38.9 M | 19.1 M | - | 15.4 M | 31 M | 15.4 M | - | 13.6 M | 29.2 M | 7.41 M | 7.36 M | 10.7 M | 21.3 M | 10.7 M | 6.86 M | 8.56 M | 18.5 M | 8.56 M | 2.59 M | 4.09 M | 8.95 M | 4.09 M | - | 3.1 M | 6.28 M | 3.1 M | - | 3.14 M | 6.31 M | 3.14 M |
Accounts Payables |
26.7 M | 23.5 M | 26.3 M | 30.2 M | 26.3 M | 30.2 M | 33.1 M | 31.6 M | 33.1 M | 31.6 M | 31.5 M | 28.1 M | 25.7 M | 28.1 M | 24.1 M | 30.5 M | 33.9 M | 30.5 M | 33.9 M | 30.9 M | 26.8 M | 25.6 M | 29.4 M | 27.2 M | 23.1 M | 27.2 M | 23.1 M | 23.1 M | 16.2 M | 14.1 M | 16.2 M | 18.3 M | 18.5 M | 18.3 M | 18.5 M | 18.5 M | 16.9 M | 15.1 M | 16.9 M | 16.9 M | 20.7 M | 14.2 M | 20.7 M | 13.2 M | 10.4 M | 13.2 M | 13.4 M | 13.4 M | 13.1 M | 13.6 M | 9.65 M | 9.65 M | 7.16 M | 6.66 M | 6.24 M | 6.24 M | 6.29 M | 6.54 M | 6.29 M | 6.29 M | 5.21 M | 5.73 M | 5.21 M | 5.21 M |
Accounts Receivables |
217 M | 215 M | 185 M | 184 M | 185 M | 184 M | 218 M | 224 M | 218 M | 224 M | 207 M | 205 M | 218 M | 205 M | 185 M | 174 M | 195 M | 174 M | 195 M | 202 M | 153 M | 148 M | 145 M | 123 M | 123 M | 123 M | 123 M | 123 M | 137 M | 123 M | 137 M | 115 M | 120 M | 115 M | 120 M | 120 M | 117 M | 107 M | 117 M | 117 M | 93.4 M | 110 M | 93.4 M | 70.9 M | 66.1 M | 70.9 M | 70 M | 70 M | 57.2 M | 60.9 M | 55 M | 47.9 M | 38.3 M | 42.2 M | 38.2 M | 38.2 M | 35.7 M | 35.1 M | 35.7 M | 35.7 M | 35.9 M | 34.1 M | 35.9 M | 35.9 M |
Total Inventories |
196 M | 201 M | 205 M | 203 M | 205 M | 203 M | 188 M | 185 M | 188 M | 185 M | 181 M | 186 M | 172 M | 186 M | 160 M | 150 M | 141 M | 150 M | 141 M | 128 M | 122 M | 117 M | 117 M | 106 M | 103 M | 106 M | 103 M | 103 M | 91 M | 90.9 M | 91 M | 90.9 M | 85.6 M | 90.9 M | 85.6 M | 85.6 M | 85.6 M | 66.5 M | 85.6 M | 60.2 M | 57.1 M | 70.5 M | 57.1 M | 59 M | 58.7 M | 59 M | 49.6 M | 49.6 M | 52.8 M | 52.2 M | 38.8 M | 38.8 M | 40 M | 40 M | 34.9 M | 34.9 M | 38.3 M | 38.4 M | 38.3 M | 38.3 M | 44.9 M | 42.1 M | 44.9 M | 44.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Bio-Techne Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
$ 20.43 | 2.17 % | $ 229 M |  USA |
 |
Adagene
ADAG
|
$ 1.99 | -1.73 % | $ 117 M |  China |
 |
Benitec Biopharma
BNTC
|
$ 9.51 | 10.07 % | $ 443 M | USA |
 |
Denali Therapeutics
DNLI
|
$ 20.09 | 1.88 % | $ 3.47 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.55 | -0.2 % | $ 4.79 B |  Irlanda |
 |
Editas Medicine
EDIT
|
$ 2.57 | 0.59 % | $ 228 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 29.4 | 4.0 % | $ 1.7 B | USA |
 |
Cue Biopharma
CUE
|
$ 18.93 | 5.11 % | $ 1.79 B | USA |
 |
Equillium
EQ
|
$ 1.54 | 15.79 % | $ 88.2 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.73 | 4.22 % | $ 98.4 M | USA |
 |
Pliant Therapeutics
PLRX
|
$ 0.81 | -0.12 % | $ 49.7 M | USA |
 |
Abeona Therapeutics
ABEO
|
$ 4.18 | 6.78 % | $ 221 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 4.36 | 8.19 % | $ 706 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.22 | -0.09 % | $ 3.57 B | USA |
 |
PainReform Ltd.
PRFX
|
$ 0.85 | 11.62 % | $ 551 K |  Israel |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 235.01 | 3.38 % | $ 14.3 B | Irlanda |
 |
Atossa Therapeutics
ATOS
|
$ 2.14 | 5.94 % | $ 18.4 M | USA |
 |
Liquidia Corporation
LQDA
|
$ 44.53 | 0.08 % | $ 3.83 B | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.59 | -2.16 % | $ 202 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 33.1 | 1.96 % | $ 1.9 B | USA |
 |
Ardelyx
ARDX
|
$ 2.88 | -3.85 % | $ 694 M | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.39 | -7.57 % | $ 100 M | USA |
 |
Alector
ALEC
|
$ 2.3 | 9.81 % | $ 237 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.16 | 0.43 % | $ 62.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 20.13 | 3.5 % | $ 6.31 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.65 | -0.54 % | $ 699 M |  Canada |
 |
Agenus
AGEN
|
$ 7.13 | 10.71 % | $ 212 M | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.89 | 6.83 % | $ 3.55 B | Canada |
 |
Artelo Biosciences
ARTL
|
$ 1.98 | -6.62 % | $ 375 K | USA |
 |
Immatics N.V.
IMTX
|
$ 6.36 | 2.91 % | $ 778 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.24 | -2.36 % | $ 391 K | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.14 | -8.2 % | $ 40.9 M | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.9 | 8.03 % | $ 478 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 27.98 | 4.29 % | $ 4.25 B | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.24 | 7.83 % | $ 3.23 M | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.4 | 3.23 % | $ 199 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.97 | 4.3 % | $ 417 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 28.5 | 3.04 % | $ 1.33 B | USA |
 |
Aquestive Therapeutics
AQST
|
$ 3.6 | -1.64 % | $ 385 M | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -2.16 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
$ 6.41 | -2.14 % | $ 454 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.03 | -4.93 % | $ 387 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 26.43 | 2.15 % | $ 2.61 B | USA |
 |
Fortress Biotech
FBIO
|
$ 1.86 | 0.82 % | $ 51.9 M | USA |
 |
Inhibrx
INBX
|
$ 84.71 | 5.52 % | $ 3.99 B | USA |